This placebo-controlled, double-blind, randomized pilot clinical trial will evaluate atomoxetine (Strattera®) for the treatment of cocaine dependence. Cocaine-dependent individuals, who are healthy and are seeking treatment for their substance abuse, will be randomized to receive either atomoxetine (n=25) or a matched-placebo (n=25) during a trial lasting 12 weeks; there will be a double-blind, ascending dose lead-in order to achieve maintenance on the assigned active dose safely. Contingency management procedures will be used to reinforce attendance and compliance with study procedures. Primary outcome measures will include urinalysis data assessing cocaine use.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
50
Once daily oral dosing
Once daily oral dosing - matched placebo
Straus Research Building
Lexington, Kentucky, United States
% Urine Samples Negative for Cocaine
Total % urine samples negative for benzoylecgonine over the 12-week trial
Time frame: Urines were collected 3 times per week (e.g., Monday, Wednesday and Friday) for 12 weeks
Retention
Trial retention- those who complete the 12 week dosing period
Time frame: 12-weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.